成人严重哮喘
- PMID:15849323
- doi:10.1164/rccm.200409-1181PP
成人严重哮喘
抽象的
Severe asthma remains poorly understood and frustrating to care for, partly because it is a heterogeneous disease. Patients with severe asthma disproportionately consume health care resources related to asthma. Severe asthma may develop over time, or shortly after onset of the disease. The genetic and environmental elements that may be most important in the development of severe disease are poorly understood, but likely include both allergic and nonallergic elements. Physiologically, these patients often have air trapping, airway collapsibility, and a high degree of methacholine hyperresponsiveness. Specific phenotypes of severe asthma are only beginning to be defined. However, describing severe asthma by age at onset (early- vs. late-onset) appears to describe two phenotypes that differ at immunologic, physiologic, epidemiologic, and pathologic levels. In particular, early-onset severe asthma is a more allergic-associated disease than late-onset severe asthma. In addition, patients with severe asthma can be defined on the basis of presence and type of inflammation. Severe asthma with persistent eosinophilia (of either early or late onset) is more symptomatic and has more near-fatal events. However, at least 50% of patients with severe asthma have very little identifiable inflammation. Thus, "steroid resistance" may occur at numerous levels, not all of which are caused by a lack of effect of steroids on inflammation. Treatment remains problematic, with corticosteroids remaining the most effective therapy. However, 5-lipoxygenase inhibitors, anti-IgE, and immunomodulatory drugs are also likely to have a place in treatment. Improving therapy in this disease will require a better understanding of the phenotypes involved.
类似的文章
-
严重哮喘的生理和病理异常。临床医学。2006年3月; 27(1):29-40,v。DOI:10.1016/j.ccm.2005.10.002。 临床医学。2006。 PMID:16543050 审查。
-
迪stinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation.J过敏临床免疫。2004年1月; 113(1):101-8。doi:10.1016/j.jaci.2003.10.041。 J过敏临床免疫。2004。 PMID:14713914
-
Pathology of difficult asthma.Paediatr Respir Rev. 2003 Dec;4(4):306-11. Paediatr Respir Rev. 2003。 PMID:14629953
-
Current treatment of severe asthma.Clin Exp Allergy. 2012 May;42(5):693-705. doi: 10.1111/j.1365-2222.2011.03936.x. Epub 2012 Jan 18. Clin Exp Allergy. 2012. PMID:22251278 审查。
-
Severe asthma: how can we differentiate phenotypes?瑞士医学。2009年5月16日; 139(19-20):274-7。 瑞士医学。2009。 PMID:19452289 审查。
被引用
-
严重哮喘中对伊马替尼治疗反应的系统方法:一项初步研究。J Pers Med。2021年3月25日; 11(4):240。doi:10.3390/jpm11040240。 J Pers Med。2021. PMID:33805900 Free PMC article.
-
Molecular Targets for Biological Therapies of Severe Asthma.Front Immunol. 2020 Nov 30;11:603312. doi: 10.3389/fimmu.2020.603312. eCollection 2020. Front Immunol. 2020. PMID:33329598 Free PMC article. 审查。
-
Latent-space embedding of expression data identifies gene signatures from sputum samples of asthmatic patients.BMC生物信息学。2020年10月15日; 21(1):457。doi:10.1186/s12859-020-03785-y。 BMC生物信息学。2020。 PMID:33059594 Free PMC article.
-
Fluctuation-based clustering reveals phenotypes of patients with different asthma severity.ERJ Open Res. 2020 Jul 6;6(2):00007-2019. doi: 10.1183/23120541.00007-2019. eCollection 2020 Apr. ERJ Open Res. 2020. PMID:32665951 Free PMC article.
-
迪stinct functions of eosinophils in severe asthma with type 2 phenotype: clinical implications.韩国J Intern Med。2020年7月; 35(4):823-833。doi:10.3904/kjim.2020.022。EPUB 2020年5月29日。 韩国J Intern Med。2020。 PMID:32460456 Free PMC article. 审查。
出版类型
MeSH terms
LinkOut - more resources
全文来源
Other Literature Sources
医疗的